SAN CARLOS, Calif., Oct. 6, 2015 /PRNewswire/ — Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that clinical research associated with its suite of genetic testing products will be highlighted during three scientific sessions at the American Society of Human Genetics (ASHG) annual meeting, to be held October 6–10 in Baltimore. MD.
Natera Presentations at ASHG
- Detection of SNVs and CNVs in Circulating Tumor DNA using Massively-Multiplexed PCR
Matthew Hill, Ph.D., Vice President, Research and Development, Natera
Thursday October 8, 7:45‒8:45 AM, Baltimore Convention Center, Rm 347-348, Level 3
Dr. Hill will review how Natera’s breakthrough mmPCR technology can provide highly accurate detection of both copy-number variants (CNVs) and single-nucleotide variants (SNVs) obtained from plasma in patients with cancer, with sensitivities lower than 0.5% ctDNA for the detection of CNVs and as low as 0.01% ctDNA for the detection of SNVs. Because breast, ovarian and lung cancer are driven by both CNVs and SNVs, Natera believes that its approach is well‑suited for early detection, recurrence monitoring, and therapy selection for these cancers.
- A study of X and Y chromosomal variations in a large fertile child-bearing-age-population
Paul Kezmarsky, MS, CGC, Medical Science Liaison, Natera
Thursday, October 8, 2015, Noon‒1:00 PM, Poster #2102
- Complex mitotic-origin aneuploidy in human embryos: Genetic risk factors and fertility consequences
Rajiv McCoy, Ph.D., Postdoctoral Fellow, University of Washington
Thursday, October 8, 2015, 5:15 PM‒5:30 PM, Oral Presentation #148, Room #307, Level 3, Session 34
For more information about these presentations and the full suite of Natera’s genetic tests, visit booth #1001 at ASHG.
Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum™ pre-implantation genetic test for embryo selection during IVF; the Anora™ miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama™ non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.
This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding Natera’s plans to develop and launch commercially available diagnostics and monitoring technology for cancer, are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release. Subsequent events may cause these expectations to change, and Natera disclaims any obligation to update any forward-looking statements for any reason after the date of this press release. These forward-looking statements are subject to a number of known and unknown risks and uncertainties that may cause actual results to differ materially, including uncertainty in the development and commercialization of our planned future cancer products or other new products or if the results of our clinical studies do not support the use of our tests, or cannot be replicated in later studies required for regulatory approvals or clearances. These and other risks and uncertainties are discussed in greater detail in the sections entitled "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in Natera’s final prospectus related to its initial public offering, dated July 1, 2015, and in Natera’s Form 10-Q for the quarter ended June 30, 2015. Further information on potential risks that could affect actual results will be included in other filings Natera makes with the SEC from time to time. These documents are available for free on the company’s website at www.natera.com under the Investor Relations section, and on the SEC’s website at www.sec.gov.
Mike Brophy, Investor Relations, 650-249-9091 x 1471
Michael Hromadik, Media Relations, 858-442-2215
SOURCE Natera, Inc.